全文获取类型
收费全文 | 24487篇 |
免费 | 1406篇 |
国内免费 | 135篇 |
专业分类
耳鼻咽喉 | 249篇 |
儿科学 | 625篇 |
妇产科学 | 503篇 |
基础医学 | 3679篇 |
口腔科学 | 1043篇 |
临床医学 | 2178篇 |
内科学 | 5674篇 |
皮肤病学 | 669篇 |
神经病学 | 2139篇 |
特种医学 | 573篇 |
外科学 | 2229篇 |
综合类 | 58篇 |
一般理论 | 10篇 |
预防医学 | 2335篇 |
眼科学 | 477篇 |
药学 | 1645篇 |
中国医学 | 112篇 |
肿瘤学 | 1830篇 |
出版年
2024年 | 33篇 |
2023年 | 255篇 |
2022年 | 602篇 |
2021年 | 1026篇 |
2020年 | 611篇 |
2019年 | 819篇 |
2018年 | 930篇 |
2017年 | 644篇 |
2016年 | 769篇 |
2015年 | 838篇 |
2014年 | 1109篇 |
2013年 | 1405篇 |
2012年 | 2194篇 |
2011年 | 2287篇 |
2010年 | 1198篇 |
2009年 | 986篇 |
2008年 | 1688篇 |
2007年 | 1628篇 |
2006年 | 1480篇 |
2005年 | 1368篇 |
2004年 | 1188篇 |
2003年 | 1000篇 |
2002年 | 881篇 |
2001年 | 97篇 |
2000年 | 65篇 |
1999年 | 88篇 |
1998年 | 124篇 |
1997年 | 106篇 |
1996年 | 86篇 |
1995年 | 65篇 |
1994年 | 57篇 |
1993年 | 57篇 |
1992年 | 39篇 |
1991年 | 34篇 |
1990年 | 32篇 |
1989年 | 31篇 |
1988年 | 25篇 |
1987年 | 14篇 |
1986年 | 24篇 |
1985年 | 20篇 |
1984年 | 28篇 |
1983年 | 17篇 |
1982年 | 18篇 |
1981年 | 11篇 |
1980年 | 5篇 |
1979年 | 6篇 |
1978年 | 5篇 |
1977年 | 6篇 |
1974年 | 4篇 |
1966年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
Flaviu Bob Gheorghe Gluhovschi Diana Herman Ligia Petrica Gheorghe Bozdog Cristina Gluhovschi 《Renal failure》2014,36(8):1208-1214
Background and aims: In order to assess the role played by tubular epithelial cells (TEC) and interstitial vascular endothelial cells (VEC) in interstitial fibrogenesis in human glomerulonephritis, we studied the expression of markers of activated fibroblasts (α-smooth muscle actin (αSMA) and vimentin (Vim)) and of the transforming growth factor β (TGFβ), at the level of these cells. Methods: We studied retrospectively 41 renal biopsies from patients with primary and secondary glomerulonephritis [24 males, 17 females, mean age 45.5?±?12.9?years]. Immunohistochemistry using monoclonal antibodies (SMA, Vim, TGFβ) was assessed using a semiquantitative score, that was correlated with biological and histological data (quantified using a scoring system in order to assess active-inflammatory and chronic–sclerotic/fibrotic lesions). Results: The presence of SMA and Vim as markers of myofibroblasts was found in TECs and VECs. TEC Vim expression correlated with interstitial Vim expression (r?=?0.38; p?=?0.008), interstitial infiltrate (r?=?0.31; p?=?0.027), interstitial fibrosis (R?=?0.25; p?=?0.042), GFR (r?=??0.35; p?=?0.016), SMA (r?=??0.42; p?=?0.015), TGFβ (r?=?0.25; p?=?0.046), and hemoglobin (r?=??0.55; p?0.001). VEC Vim expression showed indirect correlations with interstitial infiltrate (r?=??0.32; p?=?0.023) and interstitial fibrosis (r?=??0.34; p?=?0.017). Conclusion: Our study reflects the complexity of the involvement of VEC and mainly of TEC in fibrosis. The expression of mesenchymal markers at the tubular cell level (especially Vim) correlates with histological interstitial changes, with the decrease of renal function and more strongly with anemia. 相似文献
993.
Paolo Rigotti Giovanni Capovilla Caterina Di Bella Cristina Silvestre Paola Donato Nicola Baldan Lucrezia Furian 《Clinical transplantation》2014,28(12):1433-1440
This study reports on a large series of 200 dual kidney transplantations (DKTs) from expanded criteria donors (ECDs) and proposes specific ways to optimize outcomes. Data concerning 200 DKTs performed in the last 14 yr were retrospectively analyzed. Kidneys from high‐risk ECD were allocated for use in DKTs on an old‐for‐old basis after histological assessment. Different surgical techniques and immunosuppressant regimens were used over time, and the outcomes are discussed. Donors and recipients were a median 73 (70–77) and a 62 (58–67) yr old, respectively. Delayed graft function occurred in 31.5% of cases, and acute rejection in 13.5%. Patient and graft survival at five yr were 90.4% and 85.8%, respectively. Unilateral kidney placement was preferred for 75% of patients, and was associated with a low rate of surgical complications. Our current standard therapy comprising low‐dose calcineurin inhibitors (CNIs) associated with mammalian target of rapamycin inhibitors (mTOR) and steroids appears to offer the best risk/benefit profile for elderly patients undergoing DKT. In our experience, outcomes after DKT can be improved by: (i) kidney clinical–histological assessment; (ii) unilateral kidney placement; (iii) minimal use of CNI associated with mTOR. 相似文献
994.
Patrícia Soares de Souza Elias David‐Neto Nicolas Panajotopolous Fabiana Agena Hélcio Rodrigues Carla Ronda Daísa Ribeiro David Jorge Kalil Wiliam Carlos Nahas Maria Cristina Ribeiro de Castro 《Clinical transplantation》2014,28(11):1234-1243
The purpose of this study was to sequentially monitor anti‐HLA antibodies and correlate the results with antibody‐mediated rejection (AMR), graft survival (GS), and graft function (GF). We collected sera from 111 kidney transplant recipients on transplant days 0, 7, 14, 30, 60, 90, 180, and 360 and analyzed PRA levels by ELISA. DSAs were analyzed by single‐antigen beads in rejecting kidneys. At pre‐transplant, 79.3% of the patients were non‐sensitized (PRA = 0%) and 20.7% were sensitized (PRA > 1%). After transplant, patients were grouped by PRA profile: no anti‐HLA antibodies pre‐ or post‐transplant (group HLApre?/post?; n = 80); de novo anti‐HLA antibodies post‐transplant (group HLApre?/post+; n = 8); sensitized pre‐transplant/increased PRA post‐transplant (group HLApre+/post↑; n = 9); and sensitized pre‐transplant/decreased PRA post‐transplant (group HLApre+/post↓; n = 14). De novo anti‐HLA antibodies were detected at 7–180 d. In sensitized patients, PRA levels changed within the first 30 d post‐transplant. Incidence of AMR was higher in HLApre?/post+ and HLApre+/post↑ than in HLApre?/post?, and HLApre+/post↓ (p < 0.001) groups. One‐yr death‐censored GS was 36% in group HLApre+/post↑, compared with 98%, 88% and 100% in groups HLApre?/post?, HLApre?/post+, and HLApre+/post↓, respectively (p < 0.001). Excluding first‐year graft losses, GF and GS were similar among the groups. In conclusion, post‐transplant antibody monitoring can identify recipients at higher risk of AMR. 相似文献
995.
Alberto Bettinelli Cristina Viganò Maria Cristina Provero Francesco Barretta Alessandra Albisetti Silvana Tedeschi Barbara Scicchitano Mario G. Bianchetti 《Pediatric nephrology (Berlin, Germany)》2014,29(11):2133-2138
Background
Bartter patients may be hypercalciuric. Additional abnormalities in the metabolism of calcium, phosphate, and calciotropic hormones have occasionally been reported.Methods
The metabolism of calcium, phosphate, and calciotropic hormones was investigated in 15 patients with Bartter syndrome and 15 healthy subjects.Results
Compared to the controls, Bartter patients had significantly reduced plasma phosphate {mean [interquartile range]:1.29 [1.16–1.46] vs. 1.61 [1.54–1.67] mmol/L} and maximal tubular phosphate reabsorption (1.16 [1.00–1.35] vs. 1.41 [1.37–1.47] mmol/L) and significantly increased parathyroid hormone (PTH) level (6.1 [4.5–7.7] vs. 2.8 [2.2–4.4] pmol/L). However, patients and controls did not differ in blood calcium, 25-hydroxyvitamin D, alkaline phosphatase, and osteocalcin levels. In patients, an inverse correlation (P?0.05) was noted between total plasma calcium or glomerular filtration rate and PTH concentration. A positive correlation was also noted between PTH and osteocalcin concentrations (P?0.005), as well as between chloriduria or natriuria and phosphaturia (P?0.001). No correlation was noted between calciuria and PTH concentration or between urinary or circulating phosphate and PTH.Conclusions
The results of this study demonstrate a tendency towards renal phosphate wasting and elevated circulating PTH levels in Bartter patients. 相似文献996.
Maria Fernanda Carvalho de Camargo Cristina Lucia Henriques Simone Vieira Shirlei Komi Eliseth Ribeiro Leão Paulo Cesar Koch Nogueira 《Pediatric nephrology (Berlin, Germany)》2014,29(3):439-444
Background
The aim of this report is to describe the effect of daily hemodialysis on the growth of children with end-stage renal disease (ESRD).Methods
We performed a prospective, observational study on 24 children with ESRD undergoing daily hemodialysis (DHD). The control group comprised 26 children on concurrent conventional hemodialysis (CHD), and the follow-up for both groups was 9.3?±?3.0 months. No patient received growth hormone (GH) therapy.Results
At the onset of the study, the height-for-age Z-score was ?2.12?±?1.54 in the CHD group and ?2.84?±?2.27 in the DHD group (p?=?0.313). Assuming an increase of 0.5 standard deviation scores (SDS) of the height-for-age parameter as an improvement of growth, there were 33 % of patients in the DHD group and 8 % in the CHD group (p?=?0.035). The cumulative probability of gain in height for age at 12 months was 40 % in the DHD group versus 15 % in the CHD group (p?=?0.047). Also, 98 % of patients in the DHD group had an adequate total caloric intake, whereas 38 % in the CHD group reached this goal (p?<?0.001). No patient left the study due to intensification of the dialysis modality.Conclusions
Our data show that the DHD favored a 0.5 SDS height gain in a third of patients without GH treatment. Dialysis intensification was not a cause for treatment dropouts, and DHD should be considered as a treatment for selected cases, especially small children. 相似文献997.
998.
999.
Laura Avagliano Ilaria Parenti Paolo Grazioli Elisabetta Di Fede Chiara Parodi Milena Mariani Frank J. Kaiser Angelo Selicorni Cristina Gervasini Valentina Massa 《Clinical genetics》2020,97(1):3-11
In recent years, many genes have been associated with chromatinopathies classified as “Cornelia de Lange Syndrome-like.” It is known that the phenotype of these patients becomes less recognizable, overlapping to features characteristic of other syndromes caused by genetic variants affecting different regulators of chromatin structure and function. Therefore, Cornelia de Lange syndrome diagnosis might be arduous due to the seldom discordance between unexpected molecular diagnosis and clinical evaluation. Here, we review the molecular features of Cornelia de Lange syndrome, supporting the hypothesis that “CdLS-like syndromes” are part of a larger “rare disease family” sharing multiple clinical features and common disrupted molecular pathways. 相似文献
1000.
Cristina Gil-Ortuño Patricia Sebastián-Marcos María Sabater-Molina Elisa Nicolas-Rocamora Juan R. Gimeno-Blanes María J. Fernández del Palacio 《Clinical genetics》2020,98(3):203-214
Hypertrophic cardiomyopathy (HCM) is characterized by an abnormal increase in myocardial mass that affects cardiac structure and function. HCM is the most common inherited cardiovascular disease in humans (0.2%) and the most common cardiovascular disease in cats (14.7%). Feline HCM phenotype is very similar to the phenotype found in humans, but the time frame for the development of the disease is significantly shorter. Similar therapeutic agents are used in its treatment and it has the same complications, such as heart failure, thromboembolism and sudden cardiac death. In contrast to humans, in whom thousands of genetic variants have been identified, genetic studies in cats have been limited to fragment analysis of two sarcomeric genes identifying two variants in MYBPC3 and one in MYH7. Two of these variants have also been associated with human disease. The high prevalence of the reported variants in non-affected cats hinders the assumption of their pathogenicity in heterozygotes. An in-depth review of the literature about genetic studies on feline HCM in comparison with the same disease in humans is presented here. The close similarity in the phenotype and genotype between cats and humans makes the cat an excellent model for the pathophysiological study of the disease and future therapeutic agents. 相似文献